Anatomic Pathology Laboratory Services

Comprehensive in-house end-to-end anatomic pathology lab, adjunct molecular and histology services are designed to meet your clinical trial needs 

The healthcare market landscape is quickly changing, and it is necessary to have an anatomic pathology and histology lab partner who can deliver the services you need. A comprehensive anatomic pathology strategy can be a crucial part of clinical and commercial success of your product.

Support for your anatomic pathology needs

With access to commercial clinical laboratories and a full in-house global Anatomic Pathology (AP) service with a foot print in the Americas, Europe, Asia-Pac and China, and a lab operations team who are adept at assay transfer and validation, we have the ability to support your unique study needs. We create customized solutions for every trial, based on tissue and tumor type, staining requirements, and assay need.  Download our anatomic pathology services brochure to learn more about our capabilities. 

Histology services – histology is the study of microscopic structure of tissues. We offer a wide range of histology services, from routine procedures to more highly specialized techniques, including tissue fixation, processing, sectioning, staining, immunohistochemistry, and in situ hybridization. All histological methods and procedures were devised to best preserve the cellular detail of a tissue as close to life as possible and our histotechnologists are highly trained.

Companion Diagnostic experience – Our scientific experts provide you with an optimal path to co-develop your companion diagnostic with clinical development of the therapeutic, regulatory submission and market launch.  Our integrated approach is designed so you optimize time to market and commercial success. Learn more about our companion diagnostic capabilities. 

Immunohistochemistry (IHC) -  An IHC test is used to detect the presence or absence and localization of specific proteins by using antibodies. We offer both manual and automated IHC staining on the latest commercial platforms.

Innovation– Our digital pathology solutions promote faster, more collaborative analysis through the use of innovative, leading edge products and services to enable communication of richer efficacy signals faster and more cost-effectively. Learn more about our digital pathology offering.

Globally harmonized Anatomic Pathology in-house services

We offer a quality management system that delivers high quality, dependable data for your study. All clinical laboratories across our regions ensure a globally harmonized SOP process that minimizes technical variability in your study. Our expert pathologists, histotechnologists, clinical, and laboratory staff are trained in good documentation practices, with each AP lab containing on-site experts with >20 years’ experience.

In each of our labs, we have  a goal of at least 98% achievement of turnaround time (TAT) for each study. Our Anatomic Pathology laboratories also participate in an accuracy-driven external quality assurance program (CAP Proficiency Testing) that supports our goal of achieving global harmonization, standardization and high quality results across the globe for every study.

Anatomic Pathology for biomarker development in oncology clinical trials  – We can provide customized, global laboratory anatomic pathology lab solutions specifically suited for the unique combinations of therapeutic indication and targeted mechanism-of-action driving modern oncology drug development.

PD-L1 and predictive biomarkers - In immuno-oncology, one of the most current assays is the determination of PD-L1 status in multiple different tumor types, and most of the current assays that are available are based on IHC. There are also other biomarkers of interest that are influencing combination therapy. By introduction of multiplex IHC, a little amount of tissue can show multiple large numbers of output of markers, and multiple markers can be run in the same tissue sample, in the same assay by the application of multiplex IHC. We are developing multiplex IHC assays that would better define and have a larger output from multiple markers from a small piece of tissue. We support a lot of tissue-based testing where our pathologists clearly identify and earmark the areas of tumor. These samples can be taken for downstream molecular analysis, or for ctDNAs or other sequencing methodologies where our experienced pathologists are able to assure the quality of the sample.

Industry Trends Our Testing Solutions
Less Invasive Sampling
  • Liquid biopsy: cell free nucleic acids and circulating tumor cells (CTCs)
  • Mutation detection including Next Generation Sequencing
  • Flow cytometry, immunoassays, proteomics
Shift toward molecular methods
  • Next generation sequencing (NGS) replacing FISH panels
  • Gene expression panels replacing multiple IHCs
Ultra-high sensitivity
  • Mutation detection at < 0.01%
  • Single-cell analysis by flow cytometry/molecular platforms
  • Detection of disease and early resistance
Companion Diagnostics
  • Already established for many methods
  • Expanding to genomics/NGS platforms

Experience predicting and assessing a patient’s response to checkpoint inhibitors is an integral function to immuno-oncology drug development. Once a tissue sample is received, central AP testing is performed, and data can be mined for immuno-oncology characterizations, such as PD-L1 proteins or tumor-infiltrating lymphocytes.  We then take those characterizations and apply them to drug studies, such as the creation of predictive biomarkers for patient selection.

Anatomic Pathology lab partner for your success

Q2 Solutions has the breadth and depth of scientific experience and expertise across all major therapeutic areas, which help drug developers effectively gain a competitive advantage – helping ensure your success in clinical trials, regulatory approvals and new product launches.

We’re able to go a step further with our capability to validate, transfer, and employ new assays to meet today’s development opportunities. These abilities add significant value as we develop new assays for your trials. Learn more about our global Anatomic Pathology lab services.
Q2SM Global Anatomic Pathology Solutions

Learn how we can advance your clinical trials

Q2SM Oncology Infographic

Providing one global lab partner to support your oncology research from discovery to post-market

Adapting Clinical Trial Best Practices to a Complex Global CDx Landscape

World CDx Europe 2019

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Read More